In this article
FDA Breakthrough Therapy Designation for TECENTRIQ and Avastin
The Swiss Roche Group announced yesterday that TECENTRIQ® (atezolizumab) in combination with Avastin® (bevacizumab) has been approved by the US Food and Drug Administration (FDA) for breakthrough therapy for initial (first-line) treatment of advanced or metastatic liver Patients with cell carcinoma (HCC).
HCC is the most common type of primary liver cancer . This breakthrough therapy is based on the results of a Phase Ib study on the safety and clinical activity of TECENTRIQ combined with Avastin.
Accelerating Treatment Development for Advanced Liver Cancer
Dr. Sandra Horning, Roche’s chief medical officer and head of global product development, said: Hepatocellular carcinoma, as a malignant tumor, has limited treatment options and is the leading cause of death worldwide. Preliminary data on the treatment of this disease with TECENTRIQ and Avastin is promising. We look forward to cooperating with the health department to bring this highly promising treatment plan to patients with hepatocellular carcinoma as soon as possible.
Phase Ib Study Results and Clinical Efficacy
Breakthrough Therapy Designation (BTD) aims to accelerate the development and review of new drugs for the treatment of serious or life-threatening diseases to ensure that these drugs are approved by FDA as soon as possible to benefit patients. This is not only the 22nd BTD obtained by Roche’s pharmaceutical product line, but also the 3rd BTD obtained by TECENTRIQ.
The Roche Group published data from the Phase Ib study of hepatocellular carcinoma at the American Society of Clinical Oncology (ASCO) annual meeting in June 2018. The results of the study showed that after a median follow-up of 10.3 months, remission was observed in 15 (65%) of 23 evaluable patients.
After a median follow-up of 10.3 months, the median progression-free survival (PFS), duration of remission (DOR), disease progression time (TTP), and overall survival (OS) were not reached. Of the safety-evaluable patients (n = 43), 28% (n = 12) experienced grade 3-4 treatment-related adverse events, and no treatment-related grade 5 adverse events were observed.
Roche has provided additional data in accordance with FDA requirements, and has been granted a breakthrough therapy qualification. After obtaining updated data from follow-up trials, Roche will publish the research results at a future medical conference.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.